Oak Harvest Investment Services Grows Stake in Qiagen N.V. $QGEN

Oak Harvest Investment Services grew its holdings in Qiagen N.V. (NYSE:QGEN) by 17.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 98,722 shares of the company’s stock after acquiring an additional 14,845 shares during the period. Oak Harvest Investment Services’ holdings in Qiagen were worth $4,440,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of QGEN. United Services Automobile Association bought a new position in shares of Qiagen in the 1st quarter worth approximately $239,000. Prudential Financial Inc. raised its position in shares of Qiagen by 74.9% in the 2nd quarter. Prudential Financial Inc. now owns 8,873 shares of the company’s stock worth $426,000 after acquiring an additional 3,799 shares in the last quarter. Invesco Ltd. raised its position in shares of Qiagen by 123.7% in the 2nd quarter. Invesco Ltd. now owns 1,006,025 shares of the company’s stock worth $48,350,000 after acquiring an additional 556,387 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Qiagen by 226.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the company’s stock worth $125,000 after acquiring an additional 1,802 shares in the last quarter. Finally, First Trust Advisors LP bought a new position in shares of Qiagen in the 2nd quarter worth approximately $3,639,000. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Stock Up 0.7%

QGEN stock opened at $41.24 on Friday. Qiagen N.V. has a twelve month low of $38.79 and a twelve month high of $57.81. The company has a quick ratio of 3.31, a current ratio of 3.90 and a debt-to-equity ratio of 0.44. The firm has a market cap of $8.50 billion, a PE ratio of 20.45, a price-to-earnings-growth ratio of 2.12 and a beta of 0.79. The business has a 50 day moving average of $44.04 and a 200 day moving average of $47.49.

Qiagen (NYSE:QGEN) last issued its earnings results on Wednesday, February 4th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.61 by $0.01. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.The business had revenue of $540.42 million for the quarter, compared to the consensus estimate of $528.53 million. During the same period last year, the business posted $0.61 EPS. The company’s revenue was up 3.6% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. On average, research analysts forecast that Qiagen N.V. will post 2.26 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Citigroup decreased their target price on Qiagen from $55.40 to $55.00 and set a “neutral” rating for the company in a research report on Friday, February 6th. Jefferies Financial Group reissued a “buy” rating and issued a $59.00 target price on shares of Qiagen in a research report on Thursday, February 5th. UBS Group set a $52.00 price objective on Qiagen in a research report on Monday, February 9th. Zacks Research lowered Qiagen from a “hold” rating to a “strong sell” rating in a research report on Monday, March 9th. Finally, Deutsche Bank Aktiengesellschaft raised Qiagen from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a research report on Friday, March 13th. Four equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Qiagen has an average rating of “Hold” and an average price target of $53.64.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.